Cho B C - Med Oncol, Yonsei Canc Ctr

基本信息

浏览量：65

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 37 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study

N. Reinmuth,B.C. Cho, A. Luft, J.A. Alatorre Alexander,S. Lucien Geater, K. Laktionov,S-W. Kim, G. Ursol, M. Hussein, F.L. Lim,C-T. Yang, L.H. Araujo,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S44-S46

引用0浏览0引用

Durvalumab (D)

F. Griesinger, M. Johnson,B. Cho, A. Luft, J. Alatorre-Alexander, S. Geater, K. Laktionov,S. Kim, G. Ursol, M. Hussein, F. Lim,C. Yang,

PNEUMOLOGIE (2023): S7-S7

引用0浏览0引用

1441P Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study

F. Ghiringhelli, E. Felip,A. Zer,L. Greillier,A. Greystoke,N. Al-Sakaff,H-J. Helms, J.P. Pintoffl, S. Rahalkar,F.L. Lim,B.C. Cho

Annals of Oncology (2023): S819-S820

引用0浏览0引用

1324MO CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis

R.A. Soo,B.C. Cho,J-H. Kim,M-J. Ahn, K.H. Lee, A. Zimina, S. Orlov, I. Bondarenko,Y-G. Lee, L. Yueh Ni, S.S. Lee, K.H. Lee,

Annals of Oncology (2023): S764-S765

引用0浏览0引用

1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies

Y-G. Lee,J.S. Ahn,M-J. Ahn,J.H. Kang, R.A. Soo, T. Reungwetwattana,J.C-H. Yang, I. Cicin,D-W. Kim, B. Zaric, H. Go, K.C. Jahng,

Annals of Oncology (2023): S776-S776

引用0浏览0引用

Assoziation von KRAS/STK11/KEAP1 Mutationen und Outcome in der POSEIDON Studie: Durvalumab+/− Tremelimumab+Chemotherapie beim metastasierten NSCLC (mNSCLC)

N Reinmuth, S Peters,B Cho, A Luft, J Alatorre-Alexander, S Geater,S Kim, G Ursol, M Hussein, F Lim, C Yang,L Araujo,

63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.Pneumologie (2023)

引用0浏览0引用

Association of KRAS/STK11/ KEAP1 Mutations and Outcome in the POSEIDON Study: Durvalumab +/- Tremelimumab

N. Reinmuth, S. Peters,B. Cho, A. Luft, J. Alatorre-Alexander, S. Geater,S. Kim, G. Ursol, M. Hussein, F. Lim,C. Yang,L. Araujo,

PNEUMOLOGIE (2023): S6-S6

引用0浏览0引用

OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer

D. Rodriguez-Abreu,Y.-L. Wu,M. Boyer,M.C. Garassino,T.S.K. Mok,Y. Cheng,R. Hui,D.M. Kowalski,A.G. Robinson,J.R. Brahmer,T.A. Leal,G. Lopes,

Journal of Thoracic Oncology（2022）

引用1浏览0引用

JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC

M. R. Yun,M. R. Yu,K. B. Duggirala,K. Lee,A. Jo,E. Seah,C. Kim,B. C. Cho

JOURNAL OF THORACIC ONCOLOGY（2022）

引用2浏览0引用

5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON

E.B. Garon,B.C. Cho, A. Luft, J. Alatorre-Alexander,S.L. Geater, D. Trukhin,S-W. Kim, G. Ursol, M. Hussein, F.L. Lim,C-T. Yang, L.H. Araujo,

Annals of Oncology（2022）

引用2浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn